Opendata, web and dolomites

CARDIATEAM SIGNED

CARdiomyopathy in type 2 DIAbetes mellitus

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CARDIATEAM" data sheet

The following table provides information about the project.

Coordinator
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 

Organization address
address: RUE DE TOLBIAC 101
city: PARIS
postcode: 75654
website: www.inserm.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 12˙882˙500 €
 EC max contribution 6˙700˙000 € (52%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2024-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) coordinator 1˙240˙727.00
2    CONSORCIO CENTRO DE INVESTIGACION BIOMEDICA EN RED M.P. ES (MADRID) participant 655˙500.00
3    SIB INSTITUT SUISSE DE BIOINFORMATIQUE CH (GENEVE) participant 648˙000.00
4    STICHTING NETHERLANDS HEART INSTITUTE NL (UTRECHT) participant 605˙000.00
5    LUXEMBOURG INSTITUTE OF HEALTH LU (LUXEMBOURG) participant 588˙156.00
6    UNIVERSITY OF DUNDEE UK (DUNDEE) participant 550˙001.00
7    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 407˙616.00
8    OPALE FR (PARIS) participant 392˙481.00
9    INSERM TRANSFERT SA FR (PARIS) participant 310˙250.00
10    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) participant 269˙526.00
11    UNIVERSITE D'AIX MARSEILLE FR (Marseille) participant 213˙375.00
12    HOSPICES CIVILS DE LYON FR (LYON) participant 202˙708.00
13    ASSISTANCE PUBLIQUE HOPITAUX DE PARIS FR (PARIS) participant 200˙000.00
14    UNIVERSITAETSKLINIKUM AACHEN DE (AACHEN) participant 138˙750.00
15    UNIVERSITATSKLINIKUM HEIDELBERG DE (HEIDELBERG) participant 124˙975.00
16    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 94˙782.00
17    THE QUEEN'S UNIVERSITY OF BELFAST UK (BELFAST) participant 30˙000.00
18    METABRAIN RESEARCH FR (MAISONS-ALFORT) participant 28˙150.00
19    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
20    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
21    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00

Map

 Project objective

A rapidly evolving epidemic in Type 2 Diabetes (T2DM) is afflicting all ages, sexes and socioeconomic classes which includes serious comorbidities such as heart diseases. While ischaemic heart disease represents the major cause of death of T2DM patients, heart failure (80% of Heart Failure with preserved Ejection Fraction) is the second most common cardiovascular disease in T2DM patients. The aim of CARDIATEAM is to determine whether T2DM represents a central mechanism contributing to the pathogenesis and progression of a specific cardiomyopathy, called “diabetic cardiomyopathy” (DCM), assessing whether DCM is unique and distinct from the other forms of heart failure. To achieve this aim CARDIATEAM will build up a deeply phenotyped cohort, including an innovative imaging protocol, based on privileged access within the CARDIATEAM to already existing highly pertinent cohorts of diabetes and heart failure patients and control groups. Central biobanking of the cohort samples will allow detailed omics analysis that will feed together with the phenotype and imaging data into the central CARDIATEAM database. The data gathered will enable unsupervised machine-learning for clustering this heterogeneous population on phenotypic differences beyond diabetes. State-of-the-art big-data processing techniques and disease modeling will allow for controlling for common confounders such as BMI, smoking, age and blood pressure and will finally lead to the identification of new imaging and molecular biomarkers as well as understanding the taxonomy of the development and progression of DCM. Tailored preclinical models will be developed to explore the identified pathways revealing new therapeutic targets. The results of CARDIATEAM will be able to impact clinical care with the stratification of patients into risk groups of developing DCM, earlier diagnosis of DCM and an improvement of therapy thanks to better assessment of underlying pathophysiology and identification of new biomarkers.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDIATEAM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARDIATEAM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More  

PD-MIND (2019)

Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist Drug

Read More